This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.
NIHR HSRIC. Pelareorep in combination with paclitaxel for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016
Ovarian cancer is the sixth most common cancer for women in the UK. Symptoms of ovarian cancer are often vague early on, and many women are not diagnosed until after the cancer has grown and spread to other parts of the body. Less than half of women with ovarian cancer survive five years from diagnosis, with many becoming resistant to current treatments.
Pelareorep is a living virus that may kill cancer cells but not affect healthy cells. It is delivered directly into the bloodstream along with paclitaxel (a chemotherapy drug that's already used to treat ovarian cancer).
Pelareorep is currently being studied to see how well it works, and whether it is safe to use. If pelareorep is licensed for use in the UK, it will provide a new treatment option for women with ovarian, fallopian tube or peritoneal cancer that has returned despite already having received chemotherapy at least once before.
Subject indexing assigned by CRD
Fallopian Tubes; Female; Humans; Paclitaxel; Peritoneal Neoplasms; Retroperitoneal Neoplasms; Sarcoma
Country of organisation
An English language summary is available.
Address for correspondence
NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: firstname.lastname@example.org
Date abstract record published